Overview

Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.

Status:
RECRUITING

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the change in glycated hemoglobin (HbA1c) levels from baseline to 24 weeks after the combination therapy of cofrogliptin, metformin and SGLT2i (dapagliflozin) in type 2 diabetes mellitus (T2DM) patients with poor control of glucose level by metformin and SGLT2i combination therapy.

Phase:

PHASE4

Details

Lead Sponsor:

Huazhong University of Science and Technology

Collaborators:

Renmin Hospital of Wuhan University
Taihe Hospital
The First Affiliated Hospital of Nanchang University
Wuhan Central Hospital
Xiangyang No.1 People's Hospital